(Q37457676)

20 August 2017

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer (English)

1 reference

20 August 2017

1 reference

E A M Heijnsdijk

1

1 reference

20 August 2017

A der Kinderen

2

1 reference

20 August 2017

E M Wever

3

1 reference

20 August 2017

G Draisma

4

1 reference

20 August 2017

M J Roobol

5

1 reference

20 August 2017

H J de Koning

6

1 reference

20 August 2017

language of work or name

English

0 references

publication date

10 November 2009

1 reference

British Journal of Cancer

20 August 2017

1 reference

20 August 2017

101

1 reference

20 August 2017

11

1 reference

20 August 2017

1833-1838

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605422

20 August 2017

0 references

cites work

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Screening and prostate-cancer mortality in a randomized European study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Perioperative costs and charges of prostate brachytherapy and prostatectomy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Stage-specific survival of epithelial cancers in North-Holland/Flevoland, The Netherlands

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788248

Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer

2 September 2018

1 reference

12 December 2020

Cost benefit of emerging technology in localized carcinoma of the prostate

1 reference

12 December 2020

Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study

1 reference

12 December 2020

Advanced prostate cancer: course, care, and cost implications

1 reference

12 December 2020

Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

1 reference

12 December 2020

Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam

1 reference

12 December 2020

Prospective validation of active surveillance in prostate cancer: the PRIAS study

1 reference

12 December 2020

The economic and workload impact of 'backdoor' prostate-specific antigen screening on the UK National Health Service: a single-centre experience

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605422

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference

20 August 2017

1 reference